Mucin-Based Saliva Formulations
The primary mucin-based saliva substitute available commercially is Saliva Orthana, which contains porcine mucin as its active ingredient. 1
Available Formulations
Commercial Products
Saliva Orthana is the most well-documented mucin-based artificial saliva formulation in clinical guidelines. This product:
- Contains porcine mucin as the primary mucin source
- Exhibits approximately twice the viscosity of natural human saliva
- Demonstrates film-forming capability preferentially on hydrophobic substrates
- Is available as oral sprays, gels, and rinses 1, 2
Experimental/Research Formulations
While not commercially standardized, research has explored alternative mucin-based formulations:
Ceylon Spinach (Basella alba) mucilage-based formulation: Contains 0.61% flower mucilage with pseudoplastic flow properties (8.9 cP) similar to natural saliva, showing antioxidant activity and bacterial adhesion inhibition 3
Generic mucin-containing formulations: Research protocols have tested various "Saliva 1" type formulations that include mucin as a component, though specific commercial names are not standardized 4
Clinical Context and Usage
According to EULAR guidelines for Sjögren's syndrome management, saliva substitutes (including mucin-based formulations) should be:
- Reserved for patients with no salivary output as the preferred therapeutic approach
- Formulated to have neutral pH and contain fluoride and other electrolytes, mimicking natural saliva composition
- Available in multiple delivery forms: oral sprays, gels, and rinses 1
Important Considerations
Key distinction: Mucin-based formulations differ from carboxymethylcellulose-based products (like MAS 84) in their film-forming properties. While mucin-based products show superior film retention on hydrophobic surfaces, they may not perform as well as natural saliva on hydrophilic surfaces 2.
The choice between mucin-based versus other artificial saliva formulations should be guided by the degree of salivary gland dysfunction, with substitutes reserved for severe cases where glandular stimulation (non-pharmacological or pharmacological with pilocarpine/cevimeline) is not feasible 1.